Efficacy between nerve block and drug in patients undergoing gynecological oncological surgery
Phase 2
- Conditions
- Health Condition 1: C579- Malignant neoplasm of female genital organ, unspecifiedHealth Condition 2: O- Medical and Surgical
- Registration Number
- CTRI/2021/05/033449
- Lead Sponsor
- Department of Anaesthesiologypain medicine and critical care
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
1)Patient undergoing open midline incision gynecological oncology surgery
2)patient giving consent for study
Exclusion Criteria
1)patient refusing to participate
2)patients with history of local site infection
3)patients with history of allergy to local anaesthetic, induction agent and NSAIDS
4)patients with history of coagulopathy
5)patients on anticoagulant therapy for deranged INR or APTT value
6)patients with BMI more than 35 kg/ m2
7)patients with psychiatric illness
8)patients with deranged liver enzymes or serum creatinine more than 90mumol/lit
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Postoperative 24hr morphine consumption as administered by intravenous patient controlled analgesia in patients undergoing open gynaecological oncological surgeryTimepoint: Postoperative 24hr morphine consumption as administered by intravenous patient controlled analgesia in patients undergoing open gynaecological oncological surgery
- Secondary Outcome Measures
Name Time Method Cumulative analgesic consumption converted to oral morphine EquivalentTimepoint: 48hrs;Incidence of Postoperative nausea and vomitingTimepoint: Till 48hrs;Intraoperative fentanyl consumptionTimepoint: Intraoperative;Morphine consumptionTimepoint: 1-6, 6-12, 12-24hrs;Quality of recoveryTimepoint: 24 &48hrs;Sensory assessment at 30 mins by 3 point scaleTimepoint: 30 mins after block;Time to ambulateTimepoint: After recovery;Time to first activation of PCATimepoint: Time from block completion to first activation of PCA;Time to flatus and bladder a sensationTimepoint: After recovery;To observe complication such as pruritus, motor weakness, sedation, respiratory depression, hypotension, local anaesthetic systemic toxicityTimepoint: Till 48hrs;VAS score at rest and on movementTimepoint: O,2,4,6,12 24,30,36,42,48hrs